{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T16:34:20Z","timestamp":1776184460212,"version":"3.50.1"},"reference-count":54,"publisher":"Impact Journals, LLC","issue":"35","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,8,29]]},"DOI":"10.18632\/oncotarget.17510","type":"journal-article","created":{"date-parts":[[2017,4,28]],"date-time":"2017-04-28T18:17:31Z","timestamp":1493403451000},"page":"58108-58121","source":"Crossref","is-referenced-by-count":10,"title":["Differential expression of circulating biomarkers of tumor phenotype and outcomes in previously treated non-small cell lung cancer patients receiving erlotinib vs. cytotoxic chemotherapy"],"prefix":"10.18632","volume":"8","author":[{"given":"Mary Jo","family":"Fidler","sequence":"first","affiliation":[{"name":"Section of Medical Oncology, Rush University Medical Center, Chicago, IL 60612, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Casey","family":"Frankenberger","sequence":"additional","affiliation":[{"name":"Pathology, Rush University Medical Center, Chicago, IL 60612, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Seto","sequence":"additional","affiliation":[{"name":"Section of Medical Oncology, Rush University Medical Center, Chicago, IL 60612, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela C.","family":"Lobato","sequence":"additional","affiliation":[{"name":"Biochemistry, Rush University Medical Center, Chicago, IL 60612, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina L.","family":"Fhied","sequence":"additional","affiliation":[{"name":"Pathology, Rush University Medical Center, Chicago, IL 60612, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selina","family":"Sayidine","sequence":"additional","affiliation":[{"name":"Pathology, Rush University Medical Center, Chicago, IL 60612, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjib","family":"Basu","sequence":"additional","affiliation":[{"name":"Preventative Medicine, Rush University Medical Center, Chicago, IL 60612, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Pool","sequence":"additional","affiliation":[{"name":"Pathology, Rush University Medical Center, Chicago, IL 60612, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reem","family":"Karmali","sequence":"additional","affiliation":[{"name":"Hematology, Oncology and Cell Therapy at Rush University Medical Center, Chicago, IL 60612, USA"},{"name":"Present address: Division of Hematology and Oncology, Northwestern University, Chicago, IL 60612, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Batus","sequence":"additional","affiliation":[{"name":"Section of Medical Oncology, Rush University Medical Center, Chicago, IL 60612, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Rong","family":"Lie","sequence":"additional","affiliation":[{"name":"EMD Millipore Corporation, St. Charles, MO 63304, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Hayes","sequence":"additional","affiliation":[{"name":"EMD Millipore Corporation, St. Charles, MO 63304, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jehangir","family":"Mistry","sequence":"additional","affiliation":[{"name":"EMD Millipore Corporation, St. Charles, MO 63304, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Bonomi","sequence":"additional","affiliation":[{"name":"Section of Medical Oncology, Rush University Medical Center, Chicago, IL 60612, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey A.","family":"Borgia","sequence":"additional","affiliation":[{"name":"Pathology, Rush University Medical Center, Chicago, IL 60612, USA"},{"name":"Biochemistry, Rush University Medical Center, Chicago, IL 60612, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2017,4,28]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1470-2045(10)70112-1","article-title":"Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study","volume":"11","author":"Giaccone","year":"2010","journal-title":"The Lancet Oncology"},{"key":"2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer","volume":"353","author":"Findlay","year":"2005","journal-title":"N Engl J Med"},{"key":"3","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(05)67625-8","article-title":"Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)","volume":"366","author":"Carroll","year":"2005","journal-title":"Lancet"},{"key":"4","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/S1470-2045(13)70310-3","article-title":"Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial","volume":"14","author":"Ganzinelli","year":"2013","journal-title":"The Lancet Oncology"},{"key":"5","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1001\/jama.2014.3314","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis","volume":"311","author":"Heo","year":"2014","journal-title":"JAMA"},{"key":"6","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1200\/JCO.2013.52.4694","article-title":"Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA)","volume":"32","author":"Yoshimi","year":"2014","journal-title":"J Clin Oncol"},{"key":"7","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S1470-2045(15)00006-6","article-title":"Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial","volume":"16","author":"Min","year":"2015","journal-title":"Lancet Oncol"},{"key":"8","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","author":"TCGA RN","year":"2014","journal-title":"Nature"},{"key":"9","doi-asserted-by":"crossref","first-page":"172","DOI":"10.21037\/tlcr.2016.04.07","article-title":"The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer","volume":"5","author":"Nielsen","year":"2016","journal-title":"Transl Lung Cancer Res"},{"key":"10","first-page":"1794","article-title":"Epithelial to mesenchymal transition is a determinant of sensitivity to chemoradiotherapy in non-small cell lung cancer","volume":"92","author":"Okumura","year":"2016","journal-title":"Ann Thorac Surg"},{"key":"11","doi-asserted-by":"crossref","first-page":"7430","DOI":"10.1158\/1078-0432.CCR-08-0935","article-title":"Prognostic significance of epithelial-mesenchymal and mesenchymal-epithelial transition protein expression in non-small cell lung cancer","volume":"14","author":"Kristiansen","year":"2008","journal-title":"Clin Cancer Res"},{"key":"12","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.drup.2008.07.001","article-title":"Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers","volume":"11","author":"Gespach","year":"2008","journal-title":"Drug Resist Updat"},{"key":"13","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1172\/JCI36183","article-title":"Biomarkers for epithelial-mesenchymal transitions","volume":"119","author":"Neilson","year":"2009","journal-title":"J Clin Invest"},{"key":"14","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.cell.2008.03.027","article-title":"The epithelial-mesenchymal transition generates cells with properties of stem cells","volume":"133","author":"Brisken","year":"2008","journal-title":"Cell"},{"key":"15","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nrc2620","article-title":"Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits","volume":"9","author":"Weinberg","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"16","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/j.1745-7270.2008.00443.x","article-title":"New insights of epithelial-mesenchymal transition in cancer metastasis","volume":"40","author":"Zhou","year":"2008","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"17","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1158\/0008-5472.CAN-06-0479","article-title":"Genetic profiling of epithelial cells expressing E-cadherin repressors reveals a distinct role for Snail, Slug, and E47 factors in epithelial-mesenchymal transition","volume":"66","author":"Cano","year":"2006","journal-title":"Cancer Res"},{"key":"18","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1158\/1078-0432.CCR-12-1558","article-title":"An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance","volume":"19","author":"Tran","year":"2013","journal-title":"Clin Cancer Res"},{"key":"19","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1002\/ijc.28925","article-title":"Epithelial phenotype as a predictive marker for response to EGFR-TKIs in non-small cell lung cancer patients with wild-type EGFR","volume":"135","author":"Chen","year":"2014","journal-title":"Int J Cancer"},{"key":"20","doi-asserted-by":"crossref","first-page":"8686","DOI":"10.1158\/1078-0432.CCR-05-1492","article-title":"Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients","volume":"11","author":"Amler","year":"2005","journal-title":"Clin Cancer Res"},{"key":"21","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1097\/JTO.0b013e3181f77a39","article-title":"Ligands of epidermal growth factor receptor and the insulin-like growth factor family as serum biomarkers for response to epidermal growth factor receptor inhibitors in patients with advanced non-small cell lung cancer","volume":"5","author":"Linn","year":"2010","journal-title":"J Thorac Oncol"},{"key":"22","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Weinberg","year":"2011","journal-title":"Cell"},{"key":"23","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1517\/14728222.2010.511617","article-title":"HIF, hypoxia and the role of angiogenesis in non-small cell lung cancer","volume":"14","author":"Kim","year":"2010","journal-title":"Expert Opin Ther Targets"},{"key":"24","doi-asserted-by":"crossref","first-page":"5928","DOI":"10.1158\/1078-0432.CCR-10-1360","article-title":"Hypoxia and hypoxia-inducible factors: master regulators of metastasis","volume":"16","author":"Kang","year":"2010","journal-title":"Clin Cancer Res"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Ren, Su, Wang, Li, Fan, Li, Li, Zhao, Wu, Hou, He, Gao, Chen, et al. Epithelial phenotype as a predictive marker for response to EGFR-TKIs in non-small cell lung cancer patients with wild-type EGFR. Int J Cancer. 2014.","DOI":"10.1002\/ijc.28925"},{"key":"26","first-page":"3785","article-title":"Prognostic value of acquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR-TKI","volume":"32","author":"Tanaka","year":"2012","journal-title":"Anticancer Res"},{"key":"27","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1054\/bjoc.2001.2018","article-title":"Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic\/molecular profile of tumours and survival","volume":"85","author":"Harris","year":"2001","journal-title":"Br J Cancer"},{"key":"28","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1111\/j.1349-7006.2012.02408.x","article-title":"Hypoxia induces gefitinib resistance in non-small-cell lung cancer with both mutant and wild-type epidermal growth factor receptors","volume":"103","author":"Takahashi","year":"2012","journal-title":"Cancer Sci"},{"key":"29","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1245\/s10434-013-3330-x","article-title":"A gene signature combining the tissue expression of three angiogenic factors is a prognostic marker in early-stage non-small cell lung cancer","volume":"21","author":"Camps","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"30","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/1756-9966-28-150","article-title":"The effects of HIF-1alpha on gene expression profiles of NCI-H446 human small cell lung cancer cells","volume":"28","author":"Shan","year":"2009","journal-title":"J Exp Clin Cancer Res"},{"key":"31","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1007\/s13277-013-0842-8","article-title":"Matrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets","volume":"34","author":"Uhlin-Hansen","year":"2013","journal-title":"Tumour Biol"},{"key":"32","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1183\/09031936.00146510","article-title":"Series \u201cmatrix metalloproteinases in lung health and disease\u201d: Biological role of matrix metalloproteinases: a critical balance","volume":"38","author":"Franzke","year":"2011","journal-title":"Eur Respir J"},{"key":"33","doi-asserted-by":"crossref","unstructured":"Laviano, Koverech, Mari. Cachexia: clinical features when inflammation drives malnutrition. Proc Nutr Soc. 2015; pp. 1\u20137.","DOI":"10.1017\/S0029665115000117"},{"key":"34","doi-asserted-by":"crossref","unstructured":"Chacon-Cabrera, Fermoselle, Urtreger, Mateu-Jimenez, Diament, de Kier Joffe, Sandri, Barreiro. Pharmacological Strategies in Lung Cancer-Induced Cachexia: Effects on Muscle Proteolysis, Autophagy, Structure, and Weakness. J Cell Physiol. 2014.","DOI":"10.1002\/jcp.24611"},{"key":"35","doi-asserted-by":"crossref","first-page":"e003697","DOI":"10.1136\/bmjopen-2013-003697","article-title":"The assessment and impact of sarcopenia in lung cancer: a systematic literature review","volume":"4","author":"Byrne","year":"2014","journal-title":"BMJ Open"},{"key":"36","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2012.06.011","article-title":"Cancer cachexia: mediators, signaling, and metabolic pathways","volume":"16","author":"Guttridge","year":"2012","journal-title":"Cell Metab"},{"key":"37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2014.01.020","article-title":"Clinically relevant determinants of body composition, function and nutritional status as mortality predictors in lung cancer patients","volume":"84","author":"Zadak","year":"2014","journal-title":"Lung Cancer"},{"key":"38","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/0960327111417271","article-title":"The relationship among acute-phase responce proteins, cytokines, and hormones in various gastrointestinal cancer types patients with cachectic","volume":"31","author":"Kotan","year":"2012","journal-title":"Hum Exp Toxicol"},{"key":"39","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.canlet.2013.05.033","article-title":"Profiles of circulating inflammatory cytokines in colorectal cancer (CRC), high cancer risk conditions, and health are distinct. Possible implications for CRC screening and surveillance","volume":"337","author":"Gamian","year":"2013","journal-title":"Cancer Lett"},{"key":"40","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000011930","article-title":"Increased serum concentration of circulating soluble receptor for interleukin-2 and its effect as a prognostic indicator in cachectic patients with gastric and colorectal cancer","volume":"56","author":"Takekawa","year":"1999","journal-title":"Oncology"},{"key":"41","doi-asserted-by":"crossref","unstructured":"Song, Zhang, Wang, Zheng, Wang. Association of interleukin-8 with cachexia from patients with low-third gastric cancer. Comp Funct Genomics. 2009; p. 212345.","DOI":"10.1155\/2009\/212345"},{"key":"42","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3892\/br.2013.54","article-title":"Elevated serum levels of vascular endothelial growth factor is effective as a marker for malnutrition and inflammation in patients with ovarian cancer","volume":"1","author":"Fujimori","year":"2013","journal-title":"Biomed Rep"},{"key":"43","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3892\/ol.2013.1735","article-title":"Serum levels of rapid turnover proteins are decreased and related to systemic inflammation in patients with ovarian cancer","volume":"7","author":"Fujimori","year":"2014","journal-title":"Oncol Lett"},{"key":"44","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nrrheum.2010.4","article-title":"IL-1 pathways in inflammation and human diseases","volume":"6","author":"Palmer","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"45","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.immuni.2013.11.010","article-title":"The interleukin-1 family: back to the future","volume":"39","author":"Mantovani","year":"2013","journal-title":"Immunity"},{"key":"46","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1586\/14737140.3.4.435","article-title":"Second-line chemotherapy for non-small cell lung cancer","volume":"3","author":"Shepherd","year":"2003","journal-title":"Expert Rev Anticancer Ther"},{"key":"47","unstructured":"Broad Institute TCGA. Genome Data Analysis Center: Analysis Overview for Lung Adenocarcinoma (Primary solid tumor cohort). Broad Institute of MIT and Harvard."},{"key":"48","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/1471-2105-12-323","article-title":"RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome","volume":"12","author":"Dewey","year":"2011","journal-title":"BMC Bioinformatics"},{"key":"49","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1214\/07-AOAS101","article-title":"On testing the significance of sets of genes","volume":"1","author":"Tibshirani","year":"2007","journal-title":"The Annals of Applied Statistics"},{"key":"50","doi-asserted-by":"crossref","unstructured":"Subramanian, Tamayo, Mootha, Mukherjee, Ebert, Gillette, Paulovich, Pomeroy, Golub, Lander, Mesirov. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102:pp. 15545\u201315550.","DOI":"10.1073\/pnas.0506580102"},{"key":"51","first-page":"25","article-title":"Gene ontology: tool for the unification of biology","volume":"25","author":"Issel-Tarver","year":"2000","journal-title":"The Gene Ontology Consortium. Nat Genet"},{"key":"52","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/01.JTO.0000268675.02744.b0","article-title":"The prognostic value of chromosome 7 polysomy in non-small cell lung cancer patients treated with gefitinib","volume":"2","author":"Bonomi","year":"2007","journal-title":"J Thorac Oncol"},{"key":"53","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/JTO.0b013e3181f7c6d4","article-title":"Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer","volume":"6","author":"Belani","year":"2011","journal-title":"J Thorac Oncol"},{"key":"54","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1200\/JCO.2006.08.1455","article-title":"Sex differences in lung cancer survival: do tumors behave differently in elderly women?","volume":"25","author":"Halm","year":"2007","journal-title":"J Clin Oncol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.17510","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T19:17:10Z","timestamp":1594840630000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.17510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,28]]},"references-count":54,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2017,8,29]]}},"alternative-id":["17510","28938541"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.17510","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,28]]}}}